In a randomized clinical trial, the fixed-dose combination of Montelukast/Desloratadine  represented an efficacious and safe alternative for second-line management in people with persistent allergic rhinitis in which monotherapies or first-line therapies don’t offer clinically relevant improvement. Investigators sought to compare the effectiveness and safety of Montelukast/Desloratadine (10 mg/5 mg) and Montelukast/Loratadine (10 mg/10 mg).

In this longitudinal, double-blind, parallel-arm, prospective, multicenter, controlled study, patients were enrolled to take one of the two medications orally every 24 hours for a period of six weeks after being diagnosed with chronic allergic rhinitis and meeting eligibility requirements. The difference in the Sino-Nasal Outcome Test (SNOT-20) score at the end of treatment served as the key effectiveness variable. Occurrence of side effects was regarded as the safety endpoint.

A total of 86 individuals were randomly allocated, and 74 of them underwent per-protocol analysis. Higher than 90% of volunteers exhibited minor symptoms or no symptoms at all at the end of the trial, according to questionnaires about disease symptoms and quality of life indicators with both therapies. Both therapies considerably reduced the disease's symptoms. Mild to moderate noxious effects were noted. Hence, the combination of Desloratadine and Montelukast is a good treatment option that remarkably improves the signs and symptoms of persistent allergic rhinitis.